The phase 3 open-label, randomized NIAGARA trial was designed to evaluate the benefits of adding perioperative immunotherapy durvalumab to standard…
Cristina Suárez
Results of the phase III LITESPARK-005 clinical trial show that treatment with belzutifan versus everolimus significantly improves progression-free survival in…
Presented today at the ESMO Congress 2023, results of the phase III LITESPARK-005 study show that treatment with belzutifan versus…
Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…
Led by Toni K. Choueiri at the Dana Farber Cancer Institute, Harvard Medical School in Boston (USA), the CONTACT-03 study…
Published in The New England Journal of Medicine (1) results of the phase 3 COSMIC-313 trial show that the addition…
Results of the phase II single arm, multi-site international CALYPSO study point to the efficacy of combining potent MET inhibitor…
Presented at the 2022 annual Congress of the European Society for Medical Oncology (ESMO), results from three studies co-authored by…
The phase III international CheckMate 9ER trial continues to make headlines. Now published ahead of print in The Lancet Oncology…
Kidney cancer (KC) ranks 14th in the most common cancers with 431,288 cases in 2020 and an estimated 179,368 deaths…
